Where the science of peptides becomes clear.
An education-first resource for clinicians, researchers, athletes, and curious readers exploring the modern peptide landscape — from GLP-1 agonists transforming obesity care to the regenerative and longevity peptides driving today's research conversations.
Browse by category
Explore the site
Peptides 83
Comprehensive individual peptide pages — mechanism, human and preclinical evidence, claims with verdicts, FAQs, references.
Browse peptides → Deepest hub on the siteGLP-1 Hub
Approved obesity and diabetes drugs, emerging incretin candidates, head-to-head comparisons, practical guides, and the trials reshaping the field.
Visit GLP-1 Hub → Practical guidesArticles 32
Comparison articles, side-effect timelines, practical strategies, and the questions people actually search for about GLP-1s and peptides.
Read articles → Theoretical combinationsStacks 30
Peptide combinations discussed in research and biohacker communities — with explicit evidence-grading and honest framing throughout.
Explore stacks → Calibrated takesEvidence vs Myth 24
Honest reads on contested claims — what the research actually shows, where the picture is genuinely promising, and where it's still being built.
Read calibrated takes → Frontier researchEmerging Peptides 30
Phase 3 candidates likely to reach market soon, mid-stage emerging compounds, and preclinical biology still years from clinical reality.
Track the frontier →Featured peptides
Semaglutide
Long-acting GLP-1 receptor agonist with FDA approvals across type 2 diabetes, obesity, and cardiovascular risk reduction.
Type 2 diabetes, Obesity and weight management
Tirzepatide
Dual GIP/GLP-1 receptor agonist — the first incretin co-agonist to reach the market.
Type 2 diabetes, Obesity and weight management
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist — the next-generation incretin candidate.
Obesity (Phase 3), Type 2 diabetes (Phase 3)
BPC-157
A pentadecapeptide derived from a gastric protein, widely studied in animal models for tissue protection and recovery.
Tendon and ligament recovery research, Gut protection and inflammatory bowel models
PT-141
Melanocortin-receptor agonist acting centrally on the desire-and-arousal pathway.
Hypoactive sexual desire disorder (HSDD) — FDA-approved, Erectile dysfunction (off-label and prior development)
Tesamorelin
Stabilized GHRH analog, FDA-approved for HIV-associated lipodystrophy
HIV-associated visceral adipose tissue (VAT) excess — FDA-approved, Investigational: non-alcoholic fatty liver disease
GHK-Cu
Glycyl-histidyl-lysine in complex with copper (II)
Cosmetic skin care (established), Wound healing (evidence)
MOTS-c
A 16-amino-acid peptide encoded within the mitochondrial genome — central to a new class of "mitokines."
Metabolic health and insulin sensitivity research, Exercise capacity and skeletal muscle adaptation
Established science
Peptides with multiple Phase 3 trials and regulatory approvals — including semaglutide, tirzepatide, tesamorelin, and PT-141 — represent the strongest end of the evidence spectrum.
Start with semaglutide →Active research areas
BPC-157, TB-500, MOTS-c, epitalon and others sit in the active-research zone — promising mechanisms with growing animal data and emerging human trials.
See BPC-157 →Regulatory landscape
The FDA's evolving stance on compounded peptides shapes what's available and where. We summarize the current rules and what they mean for clinicians and researchers.
Read the context →In-depth reading
Semaglutide vs tirzepatide for weight loss
Head-to-head trial data, the GIP arm that makes tirzepatide deeper, the cardiovascular evidence each has — and which one fits which patient.
Read article ArticleGLP-1 side effects week by week
A practical timeline of what to expect through the typical 6-month dose-escalation pattern, plus the management strategies that actually help.
Read article ArticleHow to avoid muscle loss on GLP-1s
What the lean-mass-loss numbers actually mean, who's at highest risk, and the evidence-based interventions that reduce loss without slowing fat loss.
Read article ArticleBest peptide stacks for fat loss in 2026
Five stacks ranked by evidence — from CagriSema-level combinations to research-peptide tier with the honest verdict on each.
Read article Evidence vs MythThe BPC-157 tendon question
Sorting the substantial preclinical data from the persistent claim that BPC-157 has been clinically validated for tendon healing.
Read article Evidence vs MythDIHEXA: the "100,000× BDNF" claim examined
Where the assay-specific in-vitro potency finding came from, why the successor program disappointed in Phase 2/3, and the HGF/MET safety questions.
Read article GLP-1 HubSemaglutide vs tirzepatide vs retatrutide
The three leading incretin therapies — mechanism, weight-loss magnitude, side effects, and access — in head-to-head detail.
Read article GLP-1 HubLatest GLP-1 research
SELECT, FLOW, STEP-HFpEF, SURMOUNT-OSA, TRIUMPH — what the most recent landmark trials are showing.
Read articleHow we weigh evidence
Every claim on this site is anchored to a tier of evidence. We are clear about what is established, what is promising, and what is still developing — without dismissing reader interest or the genuine signals in early-stage research.